A new, injectable weight-loss drug has been approved by the U.S. Food and Drug Administration. The agency on Tuesday approved Saxenda (liraglutide) for adults who are obese or for those who are ...

Saxenda (liraglutide) is a GLP-1 agonist injection pen medication used to support long-term weight loss in adults with obesity, adults with overweight and weight-related health issues, and certain ...

Saxenda Approved for Weight Management The FDA has approved Saxenda (liraglutide [rDNA origin]) injection for chronic weight management. Saxenda is the first glucagon-like peptide-1 (GLP-1) receptor ...

The FDA has approved Saxenda® (liraglutide; Novo Nordisk) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in patients aged 12 years and older with ...

Novo Nordisk’s obesity drug Saxenda, which shares the ingredient liraglutide with the company's diabetes treatment Victoza, has been shown to reduce appetite. The drug is an analog of naturally ...

The GLP-1 receptor agonist, which was first approved for adults in December 2014, is now a treatment option for adolescents with obesity ages 12-17 as adjunct to diet and exercise. More specifically, ...

The randomized, double-blind, placebo-controlled, parallel-group study (N=9340) evaluated the time from randomization to first occurrence of major adverse CV events (MACE) (non-fatal heart attack, non ...

Saxenda® (liraglutide) injection 3 mg becomes the first FDA-approved therapy to treat obesity in adolescents in more than a decade PLAINSBORO, N.J., Dec. 4, 2020 /PRNewswire/ -- Novo Nordisk today ...

World Health Organization advisors will meet next month to decide whether liraglutide will be added to the organization’s updated Essential Medicines List, making the drug available in all hospital ...